The Patent Finder
NA

Nantomics, LLC

First filing 2013
OverviewNotableFeesChangesFamiliesPatent listSources & methods

52 patents currently held

19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2034. from the record

Of the 19 now held by other companies, 6 name Nanthealth Inc. as their current owner, and 13 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2034
Next term end
35
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Digital Histopathology and Microdissection US 10,607,343
Cited by 34 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.
Ends Jul 2038 · High confidence
Also notable
Cancer Neoepitopes US 11,421,016
Cited by 28 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Ends Nov 2038 · High confidence
Also notable
Distributed Machine Learning Systems, Apparatus, and Methods US 11,461,690
Cited by 16 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2038.
Ends Mar 2038 · High confidence

Formerly held, still cited

Notable
Cited by 72 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
now held by Nanthealth, Inc.
Ends Dec 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 18 to 20, 2026 · next Dec 18
  • 2 fees due Jan 2 to 9, 2027 · next Jan 2
  • 1 fee due Feb 8, 2027
    The maintenance fee for Iterative Discovery of Neoepitopes and Adaptive Immunotherapy and Methods Therefor (US 11,717,564) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
  • 1 fee due Mar 12, 2027
    The maintenance fee for A Method of Treating a Tumor in a Patient Based on an Immune Gene Expression Signature (US 11,756,651) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
  • 3 fees due May 5 to 21, 2027 · next May 5
  • 3 fees due Jul 7 to 16, 2027 · next Jul 7
  • 1 fee due Aug 20, 2027
    The maintenance fee for Systems And Methods For Genetic Analysis Of Metastases (US 11,908,588) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
  • 1 fee due Sep 30, 2027
    The maintenance fee for Digital Histopathology and Microdissection (US 10,607,343) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
  • 4 fees due Oct 2 to 14, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 22, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 10,347,361Genome Explorer System to Process and Present Nucleotide Variations in Genome Sequence Data
In force
 · High confidence
In forceHigh confidence
US 10,323,285Proteomics Analysis and Discovery through DNA and RNA Sequencing, Systems and Methods
In force
 · High confidence
In forceHigh confidence
US 10,620,184SRM/MRM Assay for the Cyclin-Dependent Kinase Inhibitor 2A (p16) protein
In force
 · Medium confidence
In forceMedium confidence
US 10,525,040Compositions and Methods of RIT1 Inhibition
In force
 · High confidence
In forceHigh confidence
US 10,736,884Compositions and Methods of RIT1 Inhibition
In force
 · High confidence
In forceHigh confidence
US 12,404,490AGGF1 Immunogenic Compositions
In force
 · High confidence
In forceHigh confidence
US 12,793,811Systems And Methods For High-Accuracy Variant Calling
In force
 · Medium confidence
In forceMedium confidence
US 10,339,274Viral Neoepitopes and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,623,001Compositions And Methods For Viral Cancer Neoepitopes
In force
 · High confidence
In forceHigh confidence
US 12,080,382Viral Neoepitopes and Uses Thereof
In force
 · High confidence
In forceHigh confidence
10 of 52 patents shown.
Pro members see all 52.
Pro members: see all 52 patents
Also on record, not counted in the 52: 19 patents in force now held by others · 25 applications pending · 53 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited